Microbiotica and Genentech Partner to Study Microbiome Biomarkers and New IBD Therapies

Microbiotica and Genentech Partner to Study Microbiome Biomarkers and New IBD Therapies
Microbiotica, a company spun out of the Wellcome Sanger Institute, recently established a multiyear collaboration agreement with Genentech to discover, develop, and commercialize biomarkers, targets, and therapies for inflammatory bowel disease (IBD). The collaboration will focus on microbiome biomarker signatures and potential therapies based on Genentech’s IBD pipeline and on Microbiotica’s gut microbiome Reference Genome Database and Culture Collection, which enables gut bacterial identification at clinical-trial scale. Microbiotica will use its microbiome platform to analyze patient samples from clinical
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *